Special Offer: Get 50% off your first 2 months when you do one of the following
Personalized offer codes will be given in each session
Name
Marvin A. Konstam, MD
Title
Chief Scientific Officer, Cardiovascular Clinical Science Professor of Medicine and Radiology, Tufts University School of Medicine.
Bio
Marvin A. Konstam, MD, is an internationally recognized leader in heart failure research and cardiovascular drug and device development. As the Founder and Chief Scientific Officer of Cardiovascular Clinical Sciences (CCS), established in 1997, he has guided companies and investigators through every stage of clinical research, drawing on more than 30 years of experience integrating scientific rigor with regulatory expectations.
Dr. Konstam also served as Chief Physician Executive of the Cardiovascular Center at Tufts Medical Center and is Professor of Medicine and Radiology at Tufts University School of Medicine. Marv has led major heart failure programs and advanced clinical innovation for decades. A graduate of Columbia University with further training at Massachusetts General Hospital, Brigham and Women’s Hospital, and Harvard Medical School, he has played central roles in pioneering research on ventricular remodeling and in numerous cardiovascular clinical trials, including work shaping statistical and methodological approaches to evaluating therapies. His long-standing regulatory involvement includes service on the FDA’s Cardiovascular and Renal Advisory Panel and advisory work with CMS on evidence development and heart‑failure quality‑of‑care initiatives.
Dr. Konstam also served as Chief Physician Executive of the Cardiovascular Center at Tufts Medical Center and is Professor of Medicine and Radiology at Tufts University School of Medicine. Marv has led major heart failure programs and advanced clinical innovation for decades. A graduate of Columbia University with further training at Massachusetts General Hospital, Brigham and Women’s Hospital, and Harvard Medical School, he has played central roles in pioneering research on ventricular remodeling and in numerous cardiovascular clinical trials, including work shaping statistical and methodological approaches to evaluating therapies. His long-standing regulatory involvement includes service on the FDA’s Cardiovascular and Renal Advisory Panel and advisory work with CMS on evidence development and heart‑failure quality‑of‑care initiatives.
